Unleashing the Power of Spectral Shift Technology
High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection mass spectrometry (ASMS) can be limited by sensitivity or sample demand. Spectral Shift is a fluorescence-based biophysical technique used to quantify the strength of molecular interactions. It offers a powerful alternative to traditional biochemical assays and ASMS, directly quantifying protein–ligand interactions in a high-throughput format.
At SLAS 2026, WuXi AppTec scientists presented a poster describing a Spectral Shift–based direct binding assay implemented using NanoTemper Technologies’ Spectral Shift technology, enabling detection of protein–ligand interactions with high sensitivity and low material consumption. The authors showcase results that highlight Spectral Shift as a versatile HTS approach for accelerating early discovery decisions.

Poster_SLAS 2026_Unleashing the Power of Spectral Shift Technology for Ultra-High-Throughput Binding Assays
Related Content
DNA-encoded libraries have become widely used in drug discovery, and several approaches for linking chemical compounds to DNA have been...
VIEW RESOURCEAt the 2024 Protein & Antibody Engineering Summit (PEGS) Europe, Crelux presented a poster highlighting its drug discovery platform for...
VIEW RESOURCE
